Merkel cell carcinoma dependence on Bcl-2 family members for survival

Journal of Investigative Dermatology

Volumn 134, Issue 8, 2014, Pages 2241-2250

  Verhaegen, Monique E ^a   Mangelberger, Doris ^a   Weick, Jack W ^a   Vozheiko, Tracy D ^a   Harms, Paul W ^a   Nash, Kevin T ^a   Quintana, Elsa ^a,b   Baciu, Paul ^a   Johnson, Timothy M ^a,b   Bichakjian, Christopher K ^a   Dlugosz, Andrzej A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; HISTONE H3; NAVITOCLAX; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1;

ADULT; AGED; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CARCINOMA CELL; CELL COUNT; CELL DEATH; CELL FATE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; KERATINOCYTE; MALE; MELANOCYTE; MERKEL CELL TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

AGED; AGED, 80 AND OVER; ANILINE COMPOUNDS; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, MERKEL CELL; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; MALE; MERKEL CELL POLYOMAVIRUS; MICE; MIDDLE AGED; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTO-ONCOGENE PROTEINS C-BCL-2; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84904471033     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.138     Document Type: Article

References (39)

1. Allen PJ, Bowne WB, Jaques DP et al. (2005) Merkel cell carcinoma: Prognosis and treatment of patients from a single institution. J ClinOncol 23:2300-9
2. Arora R, Chang Y, Moore PS (2012a) MCV and Merkel cell carcinoma: A molecular success story. Curr Opin Virol 2:489-98
3. Arora R, Shuda M, Guastafierro A et al. (2012b) Survivin is a therapeutic target in Merkel cell carcinoma. Sci Transl Med 4:133ra56
4. Bender T, Martinou JC (2013) Where killers meet-permeabilization of the outer mitochondrial membrane during apoptosis. Cold Spring Harb Perspect Biol 5:a011106
5. Bichakjian CK, Lowe L, Lao CD et al. (2007) Merkel cell carcinoma: Critical review with guidelines for multidisciplinary management. Cancer 110: 1-12
6. Brunner M, Thurnher D, Pammer J et al. (2008) Expression of VEGF-A/C, VEGF-R2, PDGF-alpha/beta, c-kit, EGFR, Her-2/Neu, Mcl-1 and Bmi-1 in Merkel cell carcinoma. Mod Pathol 21:876-84
7. Certo M, Del Gaizo Moore V, Nishino M et al. (2006) Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9:351-65
8. Chen L, Willis SN, Wei A et al. (2005) Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17:393-403
9. Desch L, Kunstfeld R (2013) Merkel cell carcinoma: Chemotherapy and emerging new therapeutic options. J Skin Cancer 2013:327150
10. Feinmesser M, Halpern M, Fenig E et al. (1999) Expression of the apoptosisrelated oncogenes bcl-2, bax, and p53 in Merkel cell carcinoma: Can they predict treatment response and clinical outcome? Hum Pathol 30: 1367-72
11. Fischer N, Brandner J, Fuchs F et al. (2010) Detection of Merkel cell polyomavirus (MCPyV) in Merkel cell carcinoma cell lines: Cell morphology and growth phenotype do not reflect presence of the virus. Int J Cancer 126:2133-42
12. Harms PW, Patel RM, Verhaegen ME et al. (2013) Distinct gene expression profiles of viral-and nonviral-associated merkel cell carcinoma revealed by transcriptome analysis. J Invest Dermatol 133:936-45
13. Herrant M, Jacquel A, Marchetti S et al. (2004) Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene 23:7863-73
14. Houben R, Shuda M, Weinkam R et al. (2010) Merkel cell polyomavirusinfected Merkel cell carcinoma cells require expression of viral T antigens. J Virol 84:7064-72
15. Juin P, Geneste O, Gautier F et al. (2013) Decoding and unlocking the BCL-2 dependency of cancer cells. Nat Rev Cancer 13:455-65
16. Kennedy MM, Blessing K, King G et al. (1996) Expression of bcl-2 and p53 in Merkel cell carcinoma. An immunohistochemical study. Am J Dermatopathol 18:273-7
17. Konopleva M, Contractor R, Tsao T et al. (2006) Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10:375-88
18. Miller NJ, Bhatia S, Parvathaneni U et al. (2013) Emerging and mechanismbased therapies for recurrent or metastatic merkel cell carcinoma. Curr Treat Options Oncol 14:249-63
19. Molofsky AV, He S, Bydon M et al. (2005) Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev 19:1432-7
20. Park CM, Bruncko M, Adickes J et al. (2008) Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem 51:6902-15
21. Quintana E, Shackleton M, Sabel MS et al. (2008) Efficient tumour formation by single human melanoma cells. Nature 456:593-8
22. Roberts AW, Seymour JF, Brown JR et al. (2012) Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 30:488-96
23. Rosen ST, Gould VE, Salwen HR et al. (1987) Establishment and characterization of a neuroendocrine skin carcinoma cell line. Lab Invest 56:302-12
24. Sahi H, Koljonen V, Kavola H et al. (2012) Bcl-2 expression indicates better prognosis of Merkel cell carcinoma regardless of the presence of Merkel cell polyomavirus. Virchows Arch 461:553-9
25. Schlagbauer-Wadl H, Klosner G, Heere-Ress E et al. (2000) Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. J Invest Dermatol 114:725-30
26. Schrama D, Becker JC (2011) Merkel cell carcinoma-pathogenesis, clinical aspects and treatment. J Eur Acad Dermatol Venereol 25:1121-9
27. Schwartz JL, Bichakjian CK, Lowe L et al. (2013) Clinicopathologic features of primary Merkel cell carcinoma: A detailed descriptive analysis of a large contemporary cohort. Dermatol Surg 39:1009-16
28. Shah MH, Varker KA, Collamore M et al. (2009) G3139 (Genasense) in patients with advanced merkel cell carcinoma. Am J Clin Oncol 32:174-9
29. Shuda M, Feng H, Kwun HJ et al. (2008) T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci USA 105:16272-7
30. Stemple DL, Anderson DJ (1992) Isolation of a stem cell for neurons and glia from the mammalian neural crest. Cell 71:973-85
31. Tse C, Shoemaker AR, Adickes J et al. (2008) ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68:3421-8
32. van Delft MF, Wei AH, Mason KD et al. (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10:389-99
33. Van Gele M, Leonard JH, Van Roy N et al. (2002) Combined karyotyping, CGH and M-FISH analysis allows detailed characterization of unidentified chromosomal rearrangements in Merkel cell carcinoma. Int J Cancer 101:137-45
34. Verhaegen M, Bauer JA, Martin de la Vega C et al. (2006) A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res 66:11348-59
35. Vogler M, Dinsdale D, Dyer MJ et al. (2009) Bcl-2 inhibitors: Small molecules with a big impact on cancer therapy. Cell Death Differ 16:360-7
36. Voog E, Biron P, Martin JP et al. (1999) Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 85:2589-95
37. Wolter KG, Verhaegen M, Fernandez Y et al. (2007) Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins. Cell Death Differ 14:1605-16
38. Xie H, Lee L, Caramuta S et al. (2014) MicroRNA expression patterns related to merkel cell polyomavirus infection in human merkel cell carcinoma. J Invest Dermatol 134:507-17
39. Zhong Q, Gao W, Du F et al. (2005) Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121:1085-95